5-HT2A agonists: A novel therapy for functional neurological disorders?

14Citations
Citations of this article
75Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Functional neurological disorders are frequently encountered in clinical practice. They have a poor prognosis and treatment options are limited. Their etiology is unknown, but leading theories propose a disturbance of somatic self-representation: the mind perceives dysfunction of a body region despite intact motor and sensory pathways. Central to this model is the concept of an abnormal top-down cognitive influence upon sensorimotor function. There is growing interest in the use of 5-HT2A agonists in the management of neuropsychiatric conditions. Recent studies have shown that these agents induce changes in neural activity that disrupt hierarchical brain dynamics and modulate networks subserving self-related processing. Converging evidence suggests they may hold unique therapeutic potential in functional neurological disorders. This is of importance given the considerable personal and societal burden of this condition and we argue a clinical trial to test this hypothesis is warranted.

Cite

CITATION STYLE

APA

Bryson, A., Carter, O., Norman, T., & Kanaan, R. (2017, May 1). 5-HT2A agonists: A novel therapy for functional neurological disorders? International Journal of Neuropsychopharmacology. Oxford University Press. https://doi.org/10.1093/ijnp/pyx011

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free